公开(公告)号：US20210047410A1

公开(公告)日：2021-02-18

申请号：US16967065

申请日：2019-01-29

申请人： oncolmmune, Inc. ,  Children's Research Institute, Children's National Medical Center

发明人： Yang Liu ,  Pan Zheng ,  Fei Tang ,  Mingyue Liu ,  Martin Devenport ,  Xuexiang Du ,  Yan Zhang

IPC分类号： C07K16/28 ,  A61P35/00 ,  C12N5/071 ,  C12N5/0783 ,  G01N33/58

摘要： The present invention relates to compositions of anti-CTLA-4 antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for the reduction of autoimmune side effects compared to other immunotherapeutic agents.

公开(公告)号：US20220000974A1

公开(公告)日：2022-01-06

申请号：US17428784

申请日：2020-02-05

申请人： Oncolmmune, Inc. ,  Children's Research Institute, Children's National Medical Center

发明人： Yang Liu ,  Pan Zheng ,  Xu Wang ,  Martin Devenport

IPC分类号： A61K38/17 ,  C07K14/705 ,  A61P3/06 ,  A61P3/10

摘要： Provided herein are methods and compositions for lowering low-density lipoprotein cholesterol or glucose levels, and for treating subjects with prediabetes or diabetes by targeting CD24-Siglec interactions.

公开(公告)号：US11261233B2

公开(公告)日：2022-03-01

申请号：US16333888

申请日：2017-09-19

申请人： ONCOC4, INC. ,  CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Yang Liu ,  Pan Zheng ,  Martin Devenport ,  Wei Wu ,  Xuexiang Du ,  Mingyue Liu ,  Fei Tang

IPC分类号： C07K14/705 ,  C07K16/46 ,  A61K38/00 ,  A61P37/06 ,  A61P35/00 ,  C07K16/28 ,  A61K39/395 ,  C07K14/00 ,  A61K39/00

摘要： This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.

公开(公告)号：US11116726B2

公开(公告)日：2021-09-14

申请号：US15774217

申请日：2016-11-09

申请人： CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Yang Liu ,  Yin Wang ,  Yan Liu ,  Christopher Bailey ,  Pan Zheng

IPC分类号： A61K9/127 ,  A61K38/16 ,  A61K47/69 ,  A61K35/74 ,  A61P37/02 ,  A61P35/02

摘要： A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1α and/or HIF-2α includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.

公开(公告)号：US20210214458A1

公开(公告)日：2021-07-15

申请号：US17055248

申请日：2019-05-13

申请人： ONCOIMMUNE, INC. ,  CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER

发明人： Yang Liu ,  Pan Zheng ,  Rhonda Flores ,  Hung-Yen Chou ,  Zhihong Xue ,  Peiying Ye ,  Martin Devenport

IPC分类号： C07K16/28 ,  A61P35/00

摘要： Provided herein are anti-CD24 antibodies that selectively bind human CD24 expressed in cancer cells, but not human CD24 expressed in non-cancerous cells, and the use of such antibodies in cancer therapy.

公开(公告)号：US10369197B2

公开(公告)日：2019-08-06

申请号：US15572330

申请日：2016-05-06

申请人： Oncolmmune, Inc.

发明人： Yang Liu ,  Pan Zheng

IPC分类号： C07K14/705 ,  C07K16/46 ,  A61K38/17 ,  G01N33/92 ,  A61P9/10 ,  G01N33/50

摘要： The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.

公开(公告)号：US09623070B2

公开(公告)日：2017-04-18

申请号：US15234195

申请日：2016-08-11

申请人： Oncolmmune, Inc.

发明人： Yang Liu ,  Yin Wang ,  Yan Liu ,  Sami N. Malek ,  Pan Zheng

IPC分类号： A01N43/00 ,  A61K31/33 ,  A61K38/08

CPC分类号： A61K38/07 ,  A61K31/00 ,  A61K31/395 ,  A61K31/4355 ,  A61K31/498 ,  A61K31/565 ,  A61K38/08 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.

公开(公告)号：US20220098278A1

公开(公告)日：2022-03-31

申请号：US17490505

申请日：2021-09-30

申请人： Oncolmmune, Inc. ,  Children's National Medical Center

发明人： Yang Liu ,  Pan Zheng ,  Martin Devenport ,  Ning Li

IPC分类号： C07K14/705 ,  A61P25/00

摘要： The present invention relates to compositions and their use in methods of protecting and maintaining oligodendrocytes, and of treating demyelinating disorders

公开(公告)号：US20210040212A1

公开(公告)日：2021-02-11

申请号：US16967079

申请日：2019-01-29

申请人： Oncolmmune, Inc. ,  University of Maryland, Baltimore

发明人： Yang Liu ,  Pan Zheng ,  Fei Tang ,  Mingyue Liu ,  Martin Devenport ,  Xuexiang Du ,  Yan Zhang

IPC分类号： C07K16/28

摘要： This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.

公开(公告)号：US20220000973A1

公开(公告)日：2022-01-06

申请号：US17428769

申请日：2020-02-05

申请人： Oncolmmune, Inc. ,  University of Maryland, Baltimore

发明人： Yang Liu ,  Pan Zheng ,  Xu Wang ,  Mingyue Liu ,  Martin Devenport

IPC分类号： A61K38/17 ,  A61K47/68 ,  C07K14/705 ,  A61P3/04 ,  A61P1/16

摘要： Provided herein are methods and compositions for the prevention and treatment of nonalcoholic steatohepatitis (NASH) by targeting the CD24-Siglec axis.